David M Rabin, Nanea Reeves, Nichol Bradford
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Discussion on suitability for practicing psychedelic care professionally, and introduction of a project to advance the field.
Andrew Penn, Mary Cosimano
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Panel discusses LGBT+ perspectives on psychedelic therapy, emphasizing community's healing role. Recommendations for queer-inclusive therapy and research draw from queer history, including AIDS crisis and conversion therapy.
Alex Belser, Clancy Cavnar
Dr. Fadiman shares insights from personal psychedelic experiences and interactions with key pioneers, highlighting how psychedelics influence his Integrative Medicine philosophy and potential for global impact.
Andrew Weil
Funding for psychedelic medicine is evolving, with a rise in commercial capital alongside philanthropic support. Balancing financial interests with equitable access and learning from scaling challenges are key considerations.
Henry Elkus
Rick Doblin discusses growing up with the "queen of psychedelics", Rock and Cosmo's paths to this work, challenges of working with family, and their shared vision for the psychedelic renaissance.
Amanda Feilding, Rock Feilding-Mellen, Cosmo Fielding Mellen
Stanislav Grof, a pioneer in psychedelic research, presents the Grof® Legacy Training on 'holotropic' states of consciousness, with colleagues from international psychedelic training programs.
Brigitte Grof, Stanislav Grof, Diane Haug, Javier Charme, Neil Hannon, Jay Dufrechou
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon